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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.07.045Objective: Isolated lung perfusion is an experimental technique for the treatment of
lung metastases. Single-agent isolated lung perfusion does not result in complete
remission. We studied the in vivo and in vitro efficacy of combinations of gemcit-
abine, cisplatin, and melphalan.
Methods: In vitro, using the sulforhodamine B assay, CC531s cells were incubated
with cisplatin, gemcitabine, or melphalan or with a combination of these drugs. One
drug was added at concentrations causing 25% growth inhibition, whereas the
second drug was added at variable concentrations. In vivo, left pulmonary metas-
tases were induced in Wag/Rij rats by means of intravenous injection of CC531s
adenocarcinoma cells. At day 7, rats underwent left isolated lung perfusion with
gemcitabine (n  7), cisplatin (n  9), melphalan (n  7), gemcitabine-cisplatin
(n 6), melphalan-gemcitabine (n 6), and cisplatin-melphalan (n 7). Death by
means of metastatic disease was the end point. Survival and differences in survival
were assessed by using Kaplan-Meier and log-rank testing.
Results: In vitro synergistic activity was observed for melphalan-gemcitabine,
whereas other combinations showed additive or antagonistic activity. In vivo
treated rats lived longer compared with control animals (P  .0001). In isolated
lung perfusion melphalan resulted in longer survival compared with gemcitabine
(P  .0016) and cisplatin (P  .046). Isolated lung perfusion with melphalan-
gemcitabine resulted in 67% survival of the rats after 90 days versus 0% in other
groups.
Conclusions: Isolated lung perfusion monotherapy or combination therapy with
gemcitabine, cisplatin, or melphalan resulted in significantly longer survival
compared with that seen in control animals. Isolated lung perfusion combination
therapy with melphalan-gemcitabine resulted in the best survival either in vitro
or in vivo.
Isolated lung perfusion (ILuP) with chemotherapy is an experimental surgi-cal technique for the treatment of pulmonary metastases to improve thecurrent mean 5-year survival of approximately 40% after complete surgical
resection of metastases from colorectal carcinoma, renal carcinoma, and sar-
coma.1 On the basis of the finding that cell killing of tumor cells caused by
chemotherapeutics is concentration dependent, ILuP aims to achieve higher
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models of ILuP with sarcoma and carcinoma cell lines
were set up to test the toxicity, pharmacokinetics, and
antitumor activities of several drugs, such as doxorubi-
cin, tumor necrosis factor  (TNF-), melphalan (MN),
cisplatin (Cis), fluorodeoxyuridine, and gemcitabine
(GCB).2-11 These studies showed significantly longer sur-
vivals in rats after ILuP monotherapy with GCB and MN
compared with that seen in control rats and intravenously
treated rats.7,11 Although significantly longer survival
was achieved with ILuP monotherapy, only casual com-
plete remissions were seen. MN is an alkylating agent,
and it is not cell phase specific, resulting in DNA-inter-
strand or DNA-protein cross-links and causing inhibition
of DNA synthesis. GCB is a deoxycytidine analog with
proved clinical activity in ovarian, breast, colorectal,
pancreas, bladder, small cell lung, and non–small cell
lung cancers.12,13 After entering the cell, GCB is phos-
phorylated and incorporated into the DNA. Subsequently,
one nucleotide has to be added until DNA polymerase is
not capable of proceeding (masked chain termination).
Mainly S-phase cells proved to be sensitive to GCB. In
addition to actions on DNA, GCB has some self-poten-
tiating mechanisms within the cell. Cis is a platinum
compound and has proved clinical activity against many
of the earlier mentioned types of cancer. Cis affects not
only the DNA but also the mitochondrial RNA, the
phospholipid membranes, and the cytoskeleton.
Because of their different mechanisms of cytotoxicity,
Figure 1. Dose-response curves for the combination of GCB alone
or GCB with MN or Cis.
TABLE 1. In vivo survival after different combinations
Left ILuP GCB Cis MN
Days (mean  SD) 38  1 42  3 44  2
Survival at day 90 (%) 0 0 0
P value vs MN-GCB .0004 .0015 .0007
ILuP, Isolated lung perfusion; GCB, gemcitabine; Cis, cisplatin; MN, melphwe studied the in vitro and in vivo efficacy of combina-
126 The Journal of Thoracic and Cardiovascular Surgery ● Julytions of MN, GCB, and Cis for the treatment of pulmo-
nary metastatic colorectal adenocarcinoma in a rat model
of ILuP.
Material and Methods
In Vitro
Cell line. In this study the CC531s adenocarcinoma cell line
was used to determine sensitivity for the cytotoxic effect of GCB
(2=,2=-difluorodeoxyuridine, Gemzar), MN (L-PAM, Alkeran), and
Cis (cis-diaminedichloroplatinum). CC531s is a weakly immuno-
genic carcinoma of the colon that is syngeneic for Wag rats. The
tumor is a dimethylhydrazine-induced adenocarcinoma.14
CC531s cells were cultured in RPMI-1640 medium and sup-
plemented with 10% fetal calf serum (Invitrogen, Merelbeke,
Belgium). Cultures were maintained in exponential growth in a
humidified atmosphere at 37°C under 5% CO2/95% air.
Chemicals. Cis (Sigma, Bornem, Belgium) solutions were
made in 0.9% NaCl and stored at 20°C. Solutions of 2=,2=-
difluorodeoxycytidine (Eli Lilly, Brussels, Belgium) were made in
phosphate-buffered saline (PBS; 2.7 mmol/L KCl, 136.9 mmol/L
NaCl, 1.5 mmol/L KH2PO4, and 6.5 mmol/L Na2HPO4) and stored
at 80°C. MN (Wellcome, Waterloo, Belgium) solutions were
made in dimethyl sulfoxide/0.9% NaCl (1:1), stored at80°C, and
used for 1 month.
In vitro growth inhibition experiments. Cells were harvested
from exponential-phase cultures by means of trypsinization,
counted, and plated in 48-well plates. The seeding density was 600
cells per well to ensure exponential growth during the experiments.
After plating and a 24-hour recovery period, cells were treated for
30 minutes with Cis alone, with GCB alone, or with MN alone or
with a combination of 2 drugs: one drug was added at a concen-
tration causing about 25% growth inhibition (IC25), whereas the
other drug was added at variable concentrations. Each concentra-
tion was tested 6 times within the same experiment. After 30
minutes of incubation, cells were washed with drug-free medium.
Four days after the start of treatment, cell survival was determined
by using the sulforhodamine B (SRB) assay.
The SRB assay was performed according to the method of
Skehan and colleagues15 and Papazisis and associates,16 with
minor modifications. Culture medium was aspirated before fixation
of the cells by addition of 200 L of 10% cold trichloroacetic acid.
After 1 hour of incubation at 4°C, cells were washed 5 times with
deionized water. Cells were stained with 200 L of 0.1% SRB
(ICN, Asse, Belgium) dissolved in 1% acetic acid for at least 15
minutes and subsequently washed 4 times with 1% acetic acid to
remove unbound stain. The plates were left to dry at room tem-
perature, and bound protein stain was solubilized with 200 L of
MN  GCB GCB  Cis Cis  MN Control
79  7 47  2 56  4 28  1
67 0 0 0
.0016 .011 .0000110 mmol/L unbuffered tris(hydroxymethyl)aminomethane base
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540 nm (550 Microplate Reader; Biorad, Nazareth, Belgium).
Statistical analysis The survival rates were calculated as fol-
lows:
Mean optical density of treated cells
Mean optical density of treated cells  100
The dose-response curves were fitted to the sigmoid inhibition
model as follows:
exp(survival) 1 (C ⁄ C IC50)
where C is the concentration of the drug, and  is a constant, using
WinNonlin (Pharsight, Mountain View, Calif) to calculate the con-
centration of drug causing a 50% growth inhibition value (IC50).
All data are presented as means  SD. All experiments were
performed at least 3 times. A 2-sample t test was used to compare
IC50 values.
Possible synergism is evaluated with the median drug effect
analysis method of Chou and Talalay17 and processed by the
computer program CalcuSyn (Biosoft, Cambridge, United King-
dom). Dm values (IC50 values) are calculated by extrapolation. For
the separate drugs, the respective growth inhibition parameters,
expressed as fraction affected (FA; eg, an FA of 0.25 is a growth
inhibition of 25%), were introduced. The combination index (CI)
was calculated by using the following formula:
CI [(D)]1 ⁄ (Dx)1] [(D)2 ⁄ (Dx)2] [a(D)1(D)2 ⁄ (Dx)1(Dx)2]
where a  1 for mutually nonexclusive drugs, (D)1 and (D)2 are
the doses of the separate drugs and their combination, and (Dx)1
and (Dx)2 are the doses resulting in a growth inhibition of x%.
These doses are calculated by using the following formula:
DDm[FA ⁄ (1FA)]1⁄m
where Dm is the dose required to produce 50% growth inhibition, FA
is the fraction affected, and m is the slope of the median plot. Because
CIs changed with FA, the average CIs were used. An average CI of
less than 1 indicates synergism, an average CI of greater than 1
indicates antagonism, and an average CI of 1 indicates additivity.
In Vivo
Animals. Male inbred Wag-Rij strain rats (weight, approxi-
mately 250 g), obtained from Iffa Credo (Charluff River, Bel-
gium), were used for all experiments. Animals were treated in
accordance with the Animal Welfare Act and the “Guide for the
Care and Use of Laboratory Animals” (National Institutes of
Health publication No. 86-23, revised 1985). The rats were trans-
TABLE 2. IC50 and IC25 values after in vitro exposure for 30
minutes with different concentrations of MN, GCB, or Cis
IC50 value (mmol/L) IC25 value (mmol/L)
MN 8.0 2.2 3.2 0.6
GCB 7.6 1.2 3.5 0.9
Cis 10.3 3.5 4.9 2.0
IC50, Concentration causing 50% growth inhibition; IC25, concentration
causing 25% growth inhibition; MN, melphalan; GCB, gemcitabine; Cis,
cisplatin.ported in sterile conditions, housed in suspended mesh wire cages
The Journal of Thoraciunder standard laboratory conditions, and ad libitum fed a standard
pellet diet (standard rat chow; Hope Farms, Woerden, The Neth-
erlands). The experimental protocols were approved by the Ethical
Committee of the University of Antwerp.
Left isolated lung perfusion. Left ILuP was performed accord-
ing to the technique described by Hendriks and coworkers.18 In
brief, rats were anesthetized with isoflurane in a mixture of nitrous
oxide (NO2) and oxygen (O2). Isoflurane was administered in a
concentration of 4%, and the NO2/O2 ratio was 3:1. After 5
minutes, rats were intubated with a 16-gauge Insyte-W catheter by
means of translaryngeal illumination under direct vision and af-
terward ventilated with a volume-controlled ventilator (Harvard
Rodent Ventilator, South Natick, Mass). Once connected to the
ventilator, the NO2/O2 ratio was set to 1:1 (0.5 L/min), and the rate
of ventilation was 75 strokes/min, with a tidal volume of 10
mL/kg. Subsequently, the left chest was shaved and prepared with
a 70% alcohol solution, followed by a left thoracotomy between
the fourth and fifth rib. After placing a rib retractor, the left lung
was luxated anteriorly, and the hilum was dissected free under
microscopic view (magnification 16; Carl Zeiss, Zaventem,
Belgium). The pulmonary artery and vein were clamped with
curved microvascular clips (Kleinert-Kurz WK65145). A PE-10
perfusion catheter (Becton Dickinson, Bornem, Belgium) was in-
troduced into the chest through a 16-gauge Angiocath, which was
placed through the chest wall. The PE-10 catheter was inserted into
the pulmonary artery and fixed with a 4-0 silk tie. Perfusate was
delivered through this catheter. The effluent was collected at the
venous side by using a catheter in proximity to the venotomy. The
left thorax was flushed with 2 mL of saline every 5 minutes.
In all experiments rats were perfused for 25 minutes, fol-
lowed by a 5-minute washout period with buffered starch and a
roller pump at a rate of 0.5 mL/min. At completion of the
perfusion, the arteriotomy was repaired with 10-0 nylon sutures
(Ethilon; Ethicon, Dilbeek, Belgium). No venotomy repair was
performed, but pressure was applied, with gauze placed over the
lung to control the bleeding from the venotomy. The thoracot-
omy incision was closed in layers after introduction of a 16-
gauge catheter connected to a 50-mL syringe into the left chest
cavity. When animals recovered, the chest tube and endotra-
cheal tubes were removed.
MN, GCB, and Cis solutions were prepared by reconstituting
Figure 2. Dose-response curves for the combination of Cis alone
or Cis with GCB or MN.lyophilized powder in the supplied diluent and performing appro-
c and Cardiovascular Surgery ● Volume 130, Number 1 127
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periments. The optimal dose of MN, GCB, and Cis to be admin-
istered by means of left ILuP was determined in previous
experiments.2,6,10
Induction of unilateral pulmonary metastases. At day 0, 63
rats were infused with 2.0x10E6 viable CC531s adenocarcinoma
cells through the left femoral vein while clamping the right pul-
monary artery for 10 minutes for induction of left pulmonary
metastases, as described previously.4,7 Briefly, anesthesia was
induced, as described previously. After a right thoracotomy, the rib
retractor was placed in the third intercostal space. After luxating
the right upper and middle lobe posteriorly, the right pulmonary
artery was dissected free under microscopic view (magnification
16; Carl Zeiss). Subsequently, a longitudinal incision was made
along the posterior border of the superior caval vein, and the right
main pulmonary artery was identified. Finally, an occluding
curved microvascular clamp (Kleinert-Kurz WK65145) was
placed over the main pulmonary artery. The rat was repositioned to
gain access to the left femoral vein for infusion of the tumor cells.
The clamp on the right pulmonary artery was removed after 10
minutes. The groin incision was subsequently closed with a run-
ning suture. After full lung re-expansion, the chest was closed in 3
layers with 4-0 Vicryl sutures (Ethicon, Inc, Somerville, NJ), and
the animal was allowed to recover from anesthesia.
Experiment: Survival after left IluP with MN, GCB, and
Cis. Data on survival after left IluP with MN, GCB, and Cis are
shown in Table 1. At day 0, 63 rats were infused with 2.0x10E6
viable CC531s adenocarcinoma cells through the left femoral vein
while clamping the right pulmonary artery for 10 minutes for
induction of left pulmonary metastases, as previously described.
At day 7, all rats were randomized into 7 groups. Groups 1 to 3
underwent ILuP with 2 mg/kg MN (n  7), 320 mg/kg GCB (n 
7), and 3 mg/kg Cis (n  9), respectively. Groups 4 to 6 had ILuP
with 320 mg/kg GCB combined with 3 mg/kg Cis (n 6), 2 mg/kg
MN combined with 320 mg/kg GCB (n  6), and 3 mg/kg Cis
combined with 2 mg/kg MN (n  7), respectively. Group 7 was
the untreated control group (n  21). The end point of the study
was death caused by metastatic disease or death at day 90.
Statistical analysis. Survival curves were constructed by using
the Kaplan-Meier method, and differences in survival were as-
sessed by using the log-rank test with SPSS version 11.0 for
Figure 3. Dose-response curves for the combination of MN alone
or MN with GCB or Cis.Windows (Chicago, Ill).
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In Vitro: Analysis of the Interactions Among MN,
GCB, and Cis
The IC50 and IC25 values of MN, GCB, and Cis in CC531s
cells are summarized in Table 2. The cells were less sensi-
tive for the cytotoxicity of Cis. However, the values were
not significantly different.
On the basis of these sensitivity data, combination ex-
periments were designed in which cells were exposed to the
approximate IC25 of one drug and a concentration range of
the other drug. Figure 1 shows dose-response curves for the
combination of GCB alone or in combination with MN or
Cis, Figure 2 shows dose-response curves of Cis alone or in
combination with MN or GCB, and Figure 3 shows dose-
response curves of MN alone or in combination with GCB
or Cis. The IC50 values of the respective combinations are
summarized in Table 3.
The combination of GCB with the IC25 of MN resulted
in increased growth inhibition. The IC50 value is signifi-
cantly different from the IC50 value of GCB alone
(P  .010). Significantly less growth inhibition was ob-
served after combination therapy with Cis and the IC25 of
MN (P .021) and after therapy with GCB and the IC25 of
Cis (P  .044).
Survival remained unchanged after treatment of CC531s
cells with the combination of Cis with the IC25 of GCB, the
combination of MN with the IC25 of Cis, and the combi-
nation of Cis and the IC50 of GCB.
Synergism was analyzed with the median drug effect
analysis of Chou and Talalay,17 and average CIs are
shown in Table 4. Only the combination of GCB with the
IC25 of MN resulted in synergism. The other combina-
tions resulted in antagonism, and the mean CI was greater
TABLE 3. IC50 value after in vitro exposure of CC531s
adenocarcinoma cells with different combinations
IC50 P value
GCB 7.6  1.2
GCB  IC25 Cis 9.6 0.8* .044
GCB  IC25 MN 4.3 1.0* .010
Cis 10.3 3.5
Cis  IC25 GCB 8.4 1.0 .370
Cis  IC25 MN 17.2 1.7† .021
MN 8.0 2.2
MN  IC25 GCB 8.0 2.0 .828
MN  IC25 Cis 9.1 1.0 .626
IC50, Concentration causing 50% growth inhibition; GCB, gemcitabine;
IC25, concentration causing 25% growth inhibition; Cis, cisplatin; MN,
melphalan. *P  .05 versus 2=,2=-difluorodeoxyuridine. †P  .05 vs
cis-diaminedichloroplatinum.than 1.
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and Cis
Data on survival after left ILuP with MN, GCB, and Cis are
shown in Figure 4. All rats that had left ILuP monotherapy
or combination therapy lived significantly longer compared
with untreated control animals (P .0001). None of the rats
died of contralateral lung metastases but rather because of
bulky disease at the perfused lung with direct ingrowth of
the mediastinum, thoracic wall, or diaphragm. Rats that
underwent ILuP with MN had significantly longer survivals
compared with those that underwent ILuP with Cis (P 
.046) or ILuP with GCB (P  .0016). No significant dif-
ference in survival was observed between ILuP with GCB
or Cis (P  .096).
Combination ILuP with MN-Cis resulted in significantly
longer survival compared with Cis alone (P  .029),
whereas no prolongation in survival was observed com-
pared with single-agent MN (P  .88). A significantly
longer survival was seen after combination ILuP with GCB-
Cis compared with GCB (P  .0004) and MN-Cis (P 
.028), whereas no longer survival was observed compared
with Cis (P  .36). Combination ILuP with MN-GCB
resulted in a significant extension of survival (one complete
remission) compared with GCB (P  .0005), Cis (P 
.0031), and MN-Cis (P  .046), whereas no significant
difference was observed compared with MN (P  .12).
Histologic examination of the lungs of rats that died before
90 days did not show inflammatory or fibrotic changes in
the treated left lung compared with the nontreated right
lung.
Discussion
ILuP is a surgical experimental technique for the treatment
of lung metastases on the basis of the concentration depen-
Figure 4. Kaplan-Meier survival curves for control anim
Cis with MN.
The Journal of Thoracidency of cytotoxicity of chemotherapeutic drugs.2 The tech-
nique aims to deliver high local lung levels without sys-
temic toxicity or metabolization by the kidney or liver,
resulting in a better tumor-eradicating response. Animal
studies investigating the efficacy of left ILuP with several
drugs, such as MN, GCB, fluorodeoxyuridine, TNF, doxo-
rubicin, and Cis, were promising but did not result in
complete remission, with the exception of a single rat.3-11
Because of their different mechanisms of cytotoxicity, syn-
ergistic actions were investigated in this study both in vitro and
in vivo by using combinations of MN, GCB, and Cis. ILuP
with each single drug resulted in significantly longer survival
compared with that seen in control animals, whereas survival
with MN after ILuP was better compared with that seen with
GCB and Cis.
Theoretically, GCB and Cis interact at different levels from
cellular uptake until incorporation into the DNA. GCB can
interact with the uptake of Cis or with the binding of Cis to
DNA. Otherwise, Cis can interact with the cellular uptake, the
phosphorylation, or the incorporation of GCB into DNA.19
nd animals receiving GCB with MN, GCB with Cis, and
TABLE 4. Mean combination index value after treatment
with different combinations
Mean CI
GCB  IC25 Cis 1.433
GCB  IC25 MN 0.629
Cis  IC25 GCB 1.800
Cis  IC25 MN 2.124
MN  IC25 GCB 1.274
MN  IC25 Cis 1.226
CI, Combination index; GCB, gemcitabine; IC25, concentration causing 25%
growth inhibition; Cis, cisplatin; MN, melphalan.als ac and Cardiovascular Surgery ● Volume 130, Number 1 129
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that the effect of GCB on the accumulation of Cis or DNA
platination by Cis might be important factors in this synergistic
action. The best synergistic effect was observed when GCB
was administered 4 hours before the addition of Cis. These
synergistic effects were confirmed by the in vitro results that
showed a significant growth inhibition after exposure of the
CC531s cells with GCB and the IC50 of Cis (P  .044, CI 
1.433). However, a nonsignificant synergistic tendency was
found in vivo when drugs were delivered simultaneously (P
.0004 compared with GCB; P  .36 compared with Cis).
Intravenous pretreatment with GCB before ILuP with Cis
might induce synergistic activity17 but was not tested in these
experiments.
The mechanism of cytotoxicity of MN is totally different
from that of GCB. MN can be activated to an alkylating agent,
resulting in DNA cross-links, whereas GCB is incorporated
into the DNA after a phosphorylation step.20 In contrast to
these small synergistic actions between GCB and alkylating
agents, the present study shows a strong and significant syn-
ergistic effect when MN is added to GCB (P  .0005 com-
pared with GCB). One rat was in complete histologic remis-
sion after death at 90 days. In vitro results confirmed this
significant synergistic activity (P  .01, CI  0.629) after
treatment with GCB and the IC50 of MN.
Finally, left ILuP with MN and Cis did not result in
synergistic action either in vivo (P  .029 compared with
Cis; P  .88 compared with MN) or in vitro.
In conclusion, left ILuP monotherapy with MN, GCB, and
Cis enhances the survival of rats with unilateral left lung
metastastic disease compared with that seen in control animals,
with MN having the best results. A synergistic tendency in
prolongation of survival was observed after left ILuP with
MN-GCB and GCB-Cis, but the strongest synergistic effects
were seen with MN-GCB.
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